Vencore Will Showcase the Intersection of Big Data, Prescriptive Analytics and Rare Disease at BIO International Convention

Chantilly, Va.—June 11, 2015—Vencore, Inc. announced today that it will be exhibiting at the 2015 BIO International Convention (BIO 2015) in Philadelphia, Pa. from June 15 through 18, 2015.  Several of its medical and data experts will be on hand to discuss the intersection of big data, prescriptive analytics and rare disease throughout the week. The health analytics team from Vencore can be found at booth #4901 in the BIOMetropolis Digital Health Zone

It is estimated that one in 10 Americans are suffering with a rare disease. While nearly 7,000 rare diseases have been identified, medical science continually adds new ones to the list. Unfortunately, because they are rare, perfectly qualified doctors may have never learned about these diseases in medical school and may have never seen a case in their practice.  For someone suffering from a rare disease, that can mean decades of delayed or inaccurate diagnosis, ineffective treatments and a significantly reduced quality of life.

Vencore’s health analytics team combines clinical knowledge and advanced analytic techniques to extract the longitudinal history of de-identified patients in order to detect patients who may be suffering from yet-undiagnosed conditions

“Combining big data with the right analytics help us find the proverbial needle in the haystack to join patients with the proper therapy,” said Mac Curtis, president and CEO of Vencore, Inc. “Vencore’s expertise in smart data analytics translates to groundbreaking and potentially life-saving applications in healthcare. The pharmaceutical industry is fast developing new drug treatments for rare diseases, and now we can help get them to the right patients by applying the right analytics and insight to extract the maximum value from big data.”

By deriving discriminating features (specialist visits, procedures, drug therapies, etc.) that describe the treatment journey of diagnosed patients, Vencore’s SiPFer™ tool applies this information against the remaining claims and/or electronic health record (EHR) data to identify patient clusters that match those treatment journeys of diagnosed patients.  This approach identifies patients who may be undiagnosed or wrongly diagnosed and helps them finally get the right care.

During the convention, Tara Grabowsky, MD, Vencore’s chief medical officer, will give two presentations:

  • “Can the integration of big data and predictive analytics overcome the challenges facing rare disease?” – 10:45 a.m., Thursday, June 18th at The Gene Lantern Theater
  • “Are privacy laws too private for rare disease patients?” – 3:45 p.m., Wednesday, June 17th at Booth #4227 at the Pennsylvania Pavilion.

Additionally, on Thursday, June 18th at 9:30 a.m. in the Digital Health Zone App Bar, Vencore will demonstrate the company’s innovative prescriptive analytics.

“At Vencore, we believe that, the role of the healthcare professional will be transformed as more medical data is collected,” said Dr. Grabowsky.  “There are an estimated 55 million people with rare disease in the United States and the European Union alone. Let’s start finding them.”

The BIO International Convention, the world’s largest biotechnology gathering, regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education.